These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7910041)

  • 1. Beriate-P study.
    Gringeri A
    Ann Hematol; 1994; 68 Suppl 3():S53-4. PubMed ID: 7910041
    [No Abstract]   [Full Text] [Related]  

  • 2. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in CD4 count relative to product usage: findings from the transfusion safety study.
    Hilgartner MW
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):7-9. PubMed ID: 7903481
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinate study.
    Gomperts E
    Ann Hematol; 1994; 68 Suppl 3():S51. PubMed ID: 7910040
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclate-P--hemofil-M study.
    Seremetis S
    Ann Hematol; 1994; 68 Suppl 3():S45-7. PubMed ID: 7910038
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
    Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM
    Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII.
    Brettler D
    Ann Hematol; 1994; 68 Suppl 3():S49-50. PubMed ID: 7910039
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
    Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N
    Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clotting factor concentrated--whither purity?
    Thomas DP
    Thromb Haemost; 1995 Dec; 74(6):1604-6. PubMed ID: 8772244
    [No Abstract]   [Full Text] [Related]  

  • 10. Who should use recombinant factor VIII?
    Hoots K
    Ann Hematol; 1994; 68 Suppl 3():S65-8. PubMed ID: 8180258
    [No Abstract]   [Full Text] [Related]  

  • 11. Purity of factor VIII concentrates.
    Goudemand J; Parquet-Gernez A; Goudemand M
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):499-500. PubMed ID: 8329577
    [No Abstract]   [Full Text] [Related]  

  • 12. High purity factor VIII and immune state in HIV.
    Nurs Stand; 1993 Oct 6-12; 8(3):17. PubMed ID: 8217692
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--impact on the immune and other systems.
    Poon MC
    Ann Hematol; 1994; 68 Suppl 3():S83-6. PubMed ID: 7910044
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemofil-M study.
    Rocino A; de Biasi R
    Ann Hematol; 1994; 68 Suppl 3():S55-7. PubMed ID: 7910042
    [No Abstract]   [Full Text] [Related]  

  • 15. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
    Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
    Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
    Klamroth R; Holzhauer S; Zimmermann R; Heller C; Kurnik K;
    Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
    Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
    Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of transmission of human immunodeficiency virus (HIV) by heat-treated factor VIII concentrates in patients with severe hemophilia A.
    Daenen S; Hoogeveen Y; Smit JW; van Imhoff GW; van der Meer J; de Wolf JT; Sibinga CT; Halie RM
    Transfusion; 1987; 27(6):482-4. PubMed ID: 3120376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purity of factor VIII concentrates and immune function in hemophiliacs.
    Farrugia A
    Blood; 1992 May; 79(10):2800-1. PubMed ID: 1586729
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV seroconversion in haemophilic boys receiving heat-treated factor VIII concentrate.
    Williams MD; Skidmore SJ; Hill FG
    Vox Sang; 1990; 58(2):135-6. PubMed ID: 2111060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.